{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:55Z","timestamp":1790347495746,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Talimogene laherparepvec (T\u2010VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open\u2010label, dose de\u2010escalation study evaluated the safety and efficacy of T\u2010VEC in Japanese patients with unresectable stage IIIB\u2013IV melanoma. Eligible adult patients had histologically confirmed stage IIIB\u2013IVM1c cutaneous melanoma, may have received prior systemic anticancer therapy, must have had \u22651 injectable lesion, serum lactate dehydrogenase \u22641.5x upper limit of normal, ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function. T\u2010VEC was injected intralesionally (first dose, \u22644.0\u00a0ml of 10<jats:sup>6<\/jats:sup>\u00a0PFU\/ml; after 3\u2009weeks and then every 2\u2009weeks thereafter, \u22644.0\u00a0ml of 10<jats:sup>8<\/jats:sup>\u00a0PFU\/ml). Primary endpoints were dose\u2010limiting toxicities (DLTs) and durable response rate (DRR). Of 18 enrolled patients (72.2% female), 16 had received \u22651 prior line of therapy. Ten patients discontinued T\u2010VEC due to disease progression. Median (range) follow\u2010up was 20.0 (4\u201337) months. No DLTs were observed; 17 (94.4%) patients had treatment\u2010emergent adverse events (AEs). Fourteen (77.8%) patients had treatment\u2010related AEs; the most frequent were pyrexia (44.4%), malaise (16.7%), chills, decreased appetite, pruritus, and skin ulcer (11.1% each). The primary efficacy endpoint was met: 2 (11.1%) patients had a durable partial response \u22656\u00a0months. The DRR was consistent with that observed in a phase III trial of T\u2010VEC in non\u2010Asian patients. The safety profile was consistent with the patients' underlying disease and the known safety profile of T\u2010VEC.<\/jats:p>","DOI":"10.1111\/cas.15450","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T06:53:02Z","timestamp":1654239182000},"page":"2798-2806","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Isei","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[{"name":"Division of Dermatology Shizuoka Cancer Center Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Dermatology Shinshu University School of Medicine  Matsumoto, Nagano Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-8334","authenticated-orcid":false,"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East  Kashiwa\u2010shi, Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[{"name":"Division of Dermatology Niigata Cancer Center Hospital  Niigata\u2010shi, Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nagoya University Hospital  Nagoya\u2010shi, Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yi","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Keegan","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-7682","authenticated-orcid":false,"given":"Satoshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Plastic Surgery Faculty of Life Sciences Kumamoto University  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.04.029"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0607-8"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.03.002"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000375"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5941"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2110"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04867.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7837"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-007-0751-1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834012466280"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15151"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12873"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14210"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2873-x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15804"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13226"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13241"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14015"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3237-x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301885"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0033"},{"key":"e_1_2_11_27_1","unstructured":"United States Food and Drug Administration.Imlygic (talimogene laherparepvec) prescribing information.2015. Accessed May 30 2022.https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/cellular\u2010gene\u2010therapy\u2010products\/imlygic"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"e_1_2_11_29_1","unstructured":"World Health Organization.WHO handbook for reporting results of cancer treatment.1979. Accessed May 30 2022.http:\/\/apps.who.int\/iris\/bitstream\/10665\/37200\/1\/WHO_OFFSET_48.pdf"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000673"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061383"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.15450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.15450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T16:41:43Z","timestamp":1692722503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.15450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/cas.15450"],"URL":"https:\/\/doi.org\/10.1111\/cas.15450","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"2022-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}